Carolyn Bertozzi, a Stanford professor and serial biotech founder, has been awarded this year’s Nobel Prize in chemistry along with two other scientists, the Royal Swedish Academy of Sciences announced Wednesday.
She shares her prize with Morten Meldal, of the University of Copenhagen in Denmark, and K. Barry Sharpless, a former Nobel prize winner from the Scripps Research Institute in California. Meldal and Sharpless pioneered the concept of “click chemistry,” an idea describing how molecular building blocks snap together in chemical reactions.
Bertozzi took their work one step further, developing “bioorthogonal” click reactions that work inside living cells and don’t disrupt the cell’s normal chemistry. Her approach is used globally to map out cells and track biological processes, the academy said, and is behind targeted cancer treatments now being developed.
Bertozzi has also made a name for herself within the biotech industry, co-founding at least seven companies within the past 12 years. According to an interview with C&EN, her entrepreneurial push came when one of her graduate students asked for guidance in launching a company. Since then, she has continued to help launch startups based on technologies coming out of her laboratory at Stanford. The biotechs share a common foundation built on her work mapping sugar molecules called glycans that are found on cell surfaces, C&EN wrote. READ MORE
By Delilah Alvarado
Source: biopharmadive.com
With a first to market advantage, Ferring’s Rebyota has seen early positive adoption from gastroenterologists and infectious disease specialist in the first month post-launch. As part of their Launch Dynamix™: C.diff service, Spherix reports, while new monthly initiations are modest, a majority of physicians trialing Rebyota report high satisfaction.
Global biopharmaceutical firm UCB has entered an early drug discovery collaboration with Aitia. The collaboration is aimed at discovering and validating new drug targets and drug candidates that are linked to clinical endpoints causally in Huntington’s disease, a debilitating genetic disorder.
Foundry Innovation & Research 1—known by its much catchier acronym, FIRE1—announced Wednesday the close of a $25 million financing round. It was led by a pair of new investors in the company: Andera Partners and Novo Holdings, the holding and investment company that serves as the controlling shareholder for Novo Nordisk and Novozymes.
